BioPharmSignal logoBioPharmSignal

Biotech News

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

Tempest Therapeutics (TPST)Tempest TherapeuticsCompany update

Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo

Related news

TPSTTempest Therapeutics2026-09-11 12:00 EST

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

TPSTTempest Therapeutics2026-09-08 12:30 EST

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

LEGNLegend Biotech Corporation2026-09-15 12:00 EST

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

KURAKura Oncology2026-09-08 11:00 EST

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

ARGXArgenx2026-09-17 20:03 EST

argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors

View all latest news

Tempest Therapeutics

In Vivo CAR T Company Tempest Therapeutics develops next-generation CAR T therapies for autoimmune diseases and cancer. Its platform is designed to generate therapeutic CAR T cells directly inside the body using targeted mRNA and lipid nanoparticles. CD7-Targeted Delivery Tempest's proprietary delivery system targets CD7-positive T cells...

Recent company news

TPSTTempest Therapeutics2026-09-23 12:00 EST

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

TPSTTempest Therapeutics2026-09-15 20:05 EST

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

TPSTTempest Therapeutics2026-09-11 12:00 EST

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

TPSTTempest Therapeutics2026-09-08 12:30 EST

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TPSTTempest Therapeutics2026-08-13 20:26 EST

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Stock data

Close
0.81 USD
Market cap
19.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States